Thrivent Financial for Lutherans Has $4.05 Million Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Thrivent Financial for Lutherans increased its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 21.8% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 224,511 shares of the company’s stock after purchasing an additional 40,218 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Teva Pharmaceutical Industries were worth $4,046,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in TEVA. Sequoia Financial Advisors LLC raised its position in shares of Teva Pharmaceutical Industries by 0.7% in the third quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock valued at $2,025,000 after buying an additional 805 shares in the last quarter. Signaturefd LLC boosted its stake in shares of Teva Pharmaceutical Industries by 16.9% in the 3rd quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock valued at $137,000 after purchasing an additional 1,094 shares in the last quarter. QRG Capital Management Inc. grew its stake in shares of Teva Pharmaceutical Industries by 0.8% during the second quarter. QRG Capital Management Inc. now owns 144,938 shares of the company’s stock worth $2,355,000 after buying an additional 1,191 shares during the last quarter. United Services Automobile Association grew its holdings in shares of Teva Pharmaceutical Industries by 3.1% during the second quarter. United Services Automobile Association now owns 41,159 shares of the company’s stock worth $669,000 after purchasing an additional 1,249 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in Teva Pharmaceutical Industries by 105.7% during the 2nd quarter. GAMMA Investing LLC now owns 3,388 shares of the company’s stock worth $55,000 after purchasing an additional 1,741 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

TEVA has been the subject of a number of research analyst reports. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. UBS Group increased their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Finally, JPMorgan Chase & Co. increased their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

Insiders Place Their Bets

In related news, EVP Christine Fox sold 19,388 shares of the stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the sale, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This represents a 30.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA opened at $17.12 on Monday. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. The company has a market cap of $19.40 billion, a price-to-earnings ratio of -20.14, a price-to-earnings-growth ratio of 1.33 and a beta of 0.87. Teva Pharmaceutical Industries Limited has a 12 month low of $9.35 and a 12 month high of $19.31. The company has a 50-day moving average price of $17.67 and a 200-day moving average price of $17.34.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.